An observational study in Sexual Wellness and Gynecologic Cancers, sponsored by Casa di Cura Dott. Pederzoli. Recruiting at 6 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Casa di Cura Dott. Pederzoli · Observational
Study type and design This is an observational, exploratory, prospective, longitudinal (cohort), multicenter, non-profit study. Its purpose is to observe changes in sexual function over time without modifying standard clinical care pathways.
Background and rationale Sexual dysfunctions and the psychological impact of gynecological cancers are often underestimated in clinical practice, despite the World Health Organization recognizing sexual health as a fundamental right. Cultural, personal, and educational barriers frequently hinder an open and systematic discussion of sexual health.
Available literature highlights a significant deterioration in sexual quality of life and couple relationships among these patients; however, clear guidance on validated assessment tools and structured sexual counseling pathways is still lacking.
Study objectives
Primary objective: to evaluate whether and how sexual function questionnaire scores in patients and their partners change over time at different assessment time points.
Secondary objective: to identify the proportion of patients and partners who would perceive sexual counseling as useful, as well as the preferred timing for such support.
Endpoints
Primary endpoint: variation in Female Sexual Function Index (FSFI) scores in female patients and International Index of Erectile Function (IIEF-15) scores in male partners between assessment time points (T0-T1, T1-T2, T0-T2).
Secondary endpoint: perceived usefulness of sexual counseling support and preferred timing, based on questionnaire responses.
Procedures and assessment timeline Patients are enrolled at the time of diagnosis communication (T0). The same questionnaire is administered again six months after the start of treatment (T1) and twelve months after completion of therapy or surgery (T2). Participation requires written informed consent, and all data are collected in a pseudo-anonymized format. Partners are enrolled and assessed at the same time points.
Assessment tools
Patients: the validated Female Sexual Function Index (FSFI) questionnaire, plus an additional structured section exploring sexual experience, satisfaction, and difficulties.
Partners: the IIEF-15 questionnaire for male partners; for female partners, the same instruments used for patients are administered.
Collected variables Sociodemographic and clinical data, lifestyle habits, sleep quality, marital status, parity, ongoing or previous therapies, and FSFI and IIEF-15 questionnaire scores.
Sample size A total of 200 patients and 200 corresponding partners are expected to be enrolled.
Statistical analysis Data will be analyzed descriptively and longitudinally across the three time points. The primary analysis will use linear mixed-effects models for repeated measures, including random effects for subjects and fixed effects for time and relevant clinical covariates. Predefined subgroup analyses are planned. Statistical significance is set at p \< 0.05.
All patients diagnosed with gynecological cancer will be enrolled, regardless of the type of treatment proposed (surgery, concurrent chemoradiotherapy alone, neoadjuvant chemotherapy), provided they meet the inclusion criteria, do not meet any exclusion criteria (see above), and give their informed and unconditional consent to participate in the study by signing the appropriate forms. A necessary condition is that the patient's partner also provides informed and unconditional consent to participate in the study by signing the appropriate forms and agrees to complete the questionnaires within the same timeframe as the patient.
Exclusion Criteria:
Patients are enrolled at the time the diagnosis is communicated (T0). The questionnaire is administered again 6 months after the start of therapy or surgery (T1) and 12 months after completion of treatments or surgery (T2). Anamnestic and sociodemographic data of both the patient and the partner are recorded in the Case Report Form and entered into a dedicated database using a pseudo-anonymized identification code held exclusively by the Principal Investigator at the reference center. The questionnaire administered to patients includes the Female Sexual Function Index (FSFI) and a section of structured questions investigating sexual experience, satisfaction, and difficulties. Partners are also enrolled and assessed at the same time points; the International Index of Erectile Function (IIEF-15) is used for male partners, while the same assessment tools used for patients are administered to female partners.
Changes in FSFI questionnaire scores among female participants and IIEF scores among male participants across different assessment time points
Time frame: 6 months
the percentage of patients and partners who report perceiving the sex therapy support as beneficial, and their preferred timing for its initiation, based on questionnaire responses
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Casa di Cura Dott. Pederzoli